You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Bulk Pharmaceutical API Sources for TROFINETIDE


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for TROFINETIDE

Vendor Vendor Homepage Vendor Sku API Url
ChemTik ⤷  Get Started Free CTK3C8925 ⤷  Get Started Free
AKos Consulting & Solutions ⤷  Get Started Free AKOS030607026 ⤷  Get Started Free
AbaChemScene ⤷  Get Started Free CS-8154 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Trofinetide

Last updated: July 30, 2025

Introduction

Trofinetide (formerly NNZ-2591) is an investigational drug primarily designed for neurodevelopmental disorders, including Rett syndrome and fragile X syndrome. As a synthetic analog derived from the naturally occurring tripeptide glycine-proline-glutamate (GPE), trofinetide’s development hinges on the procurement and production of high-quality Active Pharmaceutical Ingredient (API). Ensuring reliable, compliant, and scalable suppliers for trofinetide API is critical for pharmaceutical companies engaged in clinical trials or commercial manufacturing. This article provides a comprehensive overview of current and potential sources for bulk trofinetide API, emphasizing considerations pertinent to drug developers and supply chain oversight.


Understanding Trofinetide API

Trofinetide’s chemical structure is based on modification of GPE, aiming to enhance blood-brain barrier permeability and pharmacokinetic profile. The synthetic process involves peptide synthesis techniques, utilizing high-quality reagents and stringent purification methods to meet pharmaceutical standards. Given its peptide nature, trofinetide API production demands specialized expertise in peptide synthesis, stringent quality control, and scalable manufacturing techniques compliant with Good Manufacturing Practice (GMP).


Key Criteria for API Suppliers

Suppliers of trofinetide API must meet several critical criteria:

  • GMP Certification: Essential for clinical and commercial application.
  • Synthetic Expertise: Proven capability in peptide synthesis, purification, and characterization.
  • Quality Assurance: Robust quality control (QC) and quality assurance (QA) systems.
  • Scale Flexibility: Ability to scale from research to commercial quantities.
  • Traceability and Documentation: Comprehensive batch documentation and compliance certifications.
  • Supply Reliability: Proven track record for timely delivery and consistent supply.

Leading Suppliers and Manufacturers of Trofinetide API

1. Established Peptide Contract Manufacturing Organizations (CMOs)

Several CMOs specializing in peptide synthesis have emerged as primary sources for GMP-grade APIs, including trofinetide. These organizations leverage advanced solid-phase peptide synthesis (SPPS) techniques, enabling high purity and batch consistency. Prominent players include:

  • Bachem
    Bachem is recognized globally for peptide manufacturing, offering GMP peptide synthesis services for clinical-stage and commercial APIs. Their extensive expertise in peptide chemistry and established quality systems make them a top candidate for trofinetide API production. Bachem’s flexible manufacturing capabilities support small to large-scale production.

  • Polypeptide Group
    The Polypeptide Group specializes in GMP peptide synthesis with experience in peptide therapeutics. Their facilities in the UK and the US provide scalable production and comprehensive analytical characterization, aligning well with trofinetide’s requirements.

  • PeptiGene
    Based in China, PeptiGene offers peptide synthesis services with GMP compliance, particularly focusing on CNS-targeting peptides. Their capacity for scale-up and competitive pricing make them an attractive source for late-stage development needs.

2. Large-Scale Pharmaceutical and Biotech Manufacturers

Some big pharma and biotech firms have in-house peptide synthesis capabilities, often collaborating with external suppliers to meet unmet demand:

  • Ligand Pharmaceuticals
    Known for their expertise in peptide and small molecule chemistry, Ligand may offer custom API synthesis, especially for compounds like trofinetide that are in clinical development.

  • Thermo Fisher Scientific
    While primarily a provider of research-grade peptides, Thermo Fisher has expanded into GMP manufacturing, offering peptide synthesis services suitable for early-phase clinical supply.

  • WuXi AppTec
    With broad geographic reach and extensive GMP manufacturing capacity, WuXi offers peptide synthesis tailored to pharmaceutical clients, including complex peptides akin to trofinetide.

3. Specialized Peptide API Producers in China

China’s rapidly expanding peptide manufacturing sector delivers cost-effective and scalable APIs, with some companies possessing GMP certification:

  • Qiangsheng Bio-Technology
    An emerging leader with GMP-certified facilities, Qiangsheng specializes in peptide synthesis, including custom peptides with specific modifications.

  • Jinan Haoyuan Chem Express (Haoyuan Group)
    Provides GMP peptide manufacturing with competitive pricing, suitable for clinical trial quantities of trofinetide.

  • Sino Biopharmaceuticals
    Offering peptide API manufacturing, Sino Biopharmaceuticals has established GMP facilities capable of producing peptides for neurotherapeutic applications.


Alternative and Emerging Sources

4. Academic and Contract Research Organizations (CROs)

  • Some academic institutions and CROs possess peptide synthesis capabilities for preclinical testing but generally do not supply GMP-grade API at commercial scale. Nevertheless, partnering with these entities can be advantageous during early development phases.

5. Custom Synthesis and Licensing Options

  • Outsourcing to Small Contract Manufacturers: Several niche peptide manufacturers offer bespoke peptide synthesis for early trials, though capacity and GMP compliance vary.

  • Licensing from Established Suppliers: Companies interested in maintaining direct control over API sourcing may negotiate licensing agreements with peptide manufacturers who hold GMP manufacturing capabilities.


Supply Chain Considerations

  • Intellectual Property (IP): Ensure non-infringement and clarity around licensing rights for synthesis processes.
  • Regulatory Compliance: Confirm suppliers hold valid GMP certifications and audit reports for quality assurance.
  • Manufacturing Scalability: Evaluate supplier capacity for scaling production aligned with clinical and commercial demands.
  • Quality Control: Verify analytical methods, impurity profiles, and stability data are provided and compliant with regulatory standards.

Conclusion

Trofinetide API sourcing balances peptide synthesis expertise, GMP compliance, scalability, and cost considerations. While leading peptide CMOs such as Bachem, Polypeptide Group, and WuXi AppTec dominate the landscape, regional players in China also offer competitive alternatives. Securing a reliable, compliant source requires due diligence in assessing quality systems, capacity, and regulatory track records. As trofinetide advances through development phases, establishing robust supply chains for the API remains central to ensuring uninterrupted clinical progression and future commercial success.


Key Takeaways

  • The quality and reliability of trofinetide API suppliers are critical for clinical success and commercial manufacturing.
  • Leading peptide CMOs such as Bachem, Polypeptide Group, and WuXi provide GMP-grade APIs with proven scalability.
  • Chinese peptide manufacturers offer cost-effective and scalable solutions but require thorough regulatory and quality assessments.
  • Close collaboration, transparency, and comprehensive quality documentation are essential in selecting a dependable API source.
  • Strategic planning for supply chain expansion should align with development milestones and regulatory pathways.

FAQs

1. What are the primary challenges in sourcing trofinetide API?
Peptide synthesis complexity, maintaining GMP standards, ensuring scalability, and managing supply chain logistics pose significant challenges.

2. Can peptide synthesis companies produce trofinetide at a commercial scale?
Yes, established GMP peptide manufacturers can scale production from research grade to commercial quantities, provided capacity and regulatory conditions align.

3. Are there regional differences in peptide API manufacturing quality?
While many reputable companies globally adhere to GMP standards, due diligence on certifications, audits, and quality systems is essential regardless of location.

4. How long does it typically take to secure GMP-grade trofinetide API?
Lead times vary but generally range from 3 to 9 months, depending on synthesis complexity, capacity, and licensing negotiations.

5. Is it possible to develop in-house synthesis for trofinetide?
Large pharmaceutical organizations with peptide chemistry capabilities may develop in-house synthesis, but this is less common due to complexity and regulatory considerations.


Sources

  1. Bachem Corporate Website
  2. Polypeptide Group
  3. WuXi AppTec
  4. Qiangsheng Bio-Technology
  5. Jinan Haoyuan Chem Express

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.